Jazz Pharma Plc (JAZZ) Stock Price, Quote & News

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymp...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 634 7800

Website: www.jazzpharma.com

Address:

Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland

Quantumup Oct. 6 at 2:06 PM

Piper Sandler reit'd $ALKS OW-$38 and said: We caught up with Alkermes senior management as part of investor meetings that we hosted in Europe. $CNTA $AXSM $JAZZ $AVDL As we move closer to results from the Phase II Vibrance-2 study in narcolepsy type 2 (NT2) for orexin 2 receptor (OX2R) agonist alixorexton sometime in November (per management expectations), we provide herein a few brief thoughts on what we believe would count as a "win" from the trial. We continue to believe that the underlying size of the treated narcolepsy (narcolepsy type 1 (NT1) and NT2 combined) and idiopathic hypersomnia (IH) populations translates into ample room for a handful of novel OX2R agonists to readily coexist. Beyond that, opportunities for the category beyond sleep/wake are very much under the broader investor radar, though we would keep in mind that visibility into these opportunities (e.g., psychiatric indications) should improve over the next 12-18 months. We reiterate our Overweight rating and $38 PT.

0 · Reply

Jack_Mehoff42069 Oct. 5 at 2:19 AM

$IXHL $LLY $JAZZ $AXSM

0 · Reply

NOOBofNASDAQ Oct. 5 at 1:22 AM

$AXSM $IXHL $JAZZ $LLY

0 · Reply

SweepCastApp Oct. 4 at 5:48 AM

$JAZZ: Unusual Options Activity Alerted CALL flow observed 101x contracts at Strike price of $135 Exp on 10/17/2025 with Premium of $45K and showing BEARISH Sentiment

0 · Reply

Thestocktraderhubzee Oct. 3 at 10:09 AM

WATCHLIST OCT 03 2025. $NFLX Netflix shares are trading lower amid continued weakness possibly after Elon Musk recently called on followers to cancel their Netflix streaming subscriptions. $CANG Cango Inc. Announces September 2025 Bitcoin Production Of 616.6 BTC With 20.55 BTC Per Day Average Output $RIOT Northland Capital Markets Maintains Outperform on Riot Platforms, Raises Price Target to $24.5 $QNTM Quantum Biopharma shares are trading higher after the company announced it received two key final reports related to its potential breakthrough drug for Multiple Sclerosis. $JAZZ FDA Approves Lurbinectedin In Combination With Atezolizumab Or Atezolizumab And Hyaluronidase-tqjs For Extensive-Stage Small Cell Lung Cancer

0 · Reply

jaydjones82 Oct. 3 at 1:13 AM

$JAZZ so great news came out about their drug receiving FDA approval and it dropped?

0 · Reply

julianbase23 Oct. 2 at 9:34 PM

$JAZZ why’s it down $7?

0 · Reply

notreload_ai Oct. 2 at 8:58 PM

The FDA approved $JAZZ Zepzelca/Tecentriq drug combo as a maintenance treatment for advanced small cell lung cancer. https://notreload.xyz/fda-approves-jazz-lung-cancer-combination-therapy/

0 · Reply

Bullish_Trader555 Oct. 2 at 7:31 PM

$JAZZ FDA approves combo of Jazz's lurbinectedin and Roche's atezolizumab for ES-SCLC (JAZZ, RHHBY) $LLY $REGN

0 · Reply

DragonTiger Oct. 2 at 4:23 PM

$JAZZ This is a Bullish Sentiment, not Bearish you dummy

0 · Reply

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Oct 2, 2025, 3:37 PM EDT - 4 days ago

US FDA approves Jazz Pharma's therapy for lung cancer

Sep 24, 2025, 10:45 AM EDT - 12 days ago

Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating

Sep 22, 2025, 7:45 AM EDT - 14 days ago

Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses

Sep 9, 2025, 7:45 AM EDT - 27 days ago

Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma

Sep 3, 2025, 1:21 PM EDT - 4 weeks ago

Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 21, 2025, 4:15 PM EDT - 6 weeks ago

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 20, 2025, 4:15 PM EDT - 6 weeks ago

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

Aug 20, 2025, 7:30 AM EDT - 6 weeks ago

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Aug 6, 2025, 3:07 PM EDT - 2 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Aug 6, 2025, 3:00 PM EDT - 2 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025, 5:33 AM EDT - 2 months ago

Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jul 22, 2025, 4:15 PM EDT - 2 months ago

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

Jul 10, 2025, 7:30 AM EDT - 3 months ago

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

Jul 7, 2025, 10:05 AM EDT - 3 months ago

Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 9:30 AM EDT - 3 months ago

Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor

Jul 1, 2025, 8:31 AM EDT - 3 months ago

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jun 10, 2025, 7:05 AM EDT - 4 months ago

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jun 9, 2025, 6:00 PM EDT - 4 months ago

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jun 2, 2025, 4:05 PM EDT - 4 months ago

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jun 2, 2025, 12:35 PM EDT - 4 months ago

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

May 29, 2025, 7:30 AM EDT - 4 months ago

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 21, 2025, 4:30 PM EDT - 4 months ago

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 21, 2025, 4:58 AM EDT - 4 months ago

Jazz Pharmaceuticals: One Step Forward, One Back

May 6, 2025, 11:06 PM EDT - 5 months ago

Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 5 months ago

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Apr 30, 2025, 4:15 PM EDT - 5 months ago

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Apr 25, 2025, 11:27 AM EDT - 5 months ago

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Apr 23, 2025, 4:15 PM EDT - 5 months ago

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Apr 22, 2025, 4:15 PM EDT - 5 months ago

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Apr 21, 2025, 4:05 PM EDT - 6 months ago

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Apr 9, 2025, 3:59 PM EDT - 6 months ago

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 8, 2025, 7:04 PM EDT - 6 months ago

Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case

Mar 26, 2025, 4:15 PM EDT - 6 months ago

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 7:30 AM EDT - 7 months ago

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting

Mar 10, 2025, 10:33 PM EDT - 7 months ago

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

CMRX

Mar 5, 2025, 8:41 AM EST - 7 months ago

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline

CMRX

Mar 5, 2025, 7:14 AM EST - 7 months ago

Jazz Pharmaceuticals to buy Chimerix for $935 million

CMRX

Mar 5, 2025, 7:00 AM EST - 7 months ago

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

CMRX

Feb 26, 2025, 3:15 PM EST - 7 months ago

Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab

Feb 25, 2025, 9:20 PM EST - 7 months ago

Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:05 PM EST - 7 months ago

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

Feb 20, 2025, 4:15 PM EST - 8 months ago

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Feb 11, 2025, 4:15 PM EST - 8 months ago

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Jan 22, 2025, 12:29 PM EST - 9 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT ONC XBI ZYME

Jan 13, 2025, 12:56 PM EST - 9 months ago

3 Oversold Biotech Names

AVDL FOLD VKTX XBI

Dec 23, 2024, 12:53 PM EST - 10 months ago

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Dec 17, 2024, 4:15 PM EST - 10 months ago

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 4:05 PM EST - 10 months ago

Jazz Pharmaceuticals Announces CEO Succession Plan

Quantumup Oct. 6 at 2:06 PM

0 · Reply

Jack_Mehoff42069 Oct. 5 at 2:19 AM

$IXHL $LLY $JAZZ $AXSM

0 · Reply

NOOBofNASDAQ Oct. 5 at 1:22 AM

$AXSM $IXHL $JAZZ $LLY

0 · Reply

SweepCastApp Oct. 4 at 5:48 AM

$JAZZ: Unusual Options Activity Alerted CALL flow observed 101x contracts at Strike price of $135 Exp on 10/17/2025 with Premium of $45K and showing BEARISH Sentiment

0 · Reply

Thestocktraderhubzee Oct. 3 at 10:09 AM

0 · Reply

jaydjones82 Oct. 3 at 1:13 AM

$JAZZ so great news came out about their drug receiving FDA approval and it dropped?

0 · Reply

julianbase23 Oct. 2 at 9:34 PM

$JAZZ why’s it down $7?

0 · Reply

notreload_ai Oct. 2 at 8:58 PM

The FDA approved $JAZZ Zepzelca/Tecentriq drug combo as a maintenance treatment for advanced small cell lung cancer. https://notreload.xyz/fda-approves-jazz-lung-cancer-combination-therapy/

0 · Reply

Bullish_Trader555 Oct. 2 at 7:31 PM

$JAZZ FDA approves combo of Jazz's lurbinectedin and Roche's atezolizumab for ES-SCLC (JAZZ, RHHBY) $LLY $REGN

0 · Reply

DragonTiger Oct. 2 at 4:23 PM

$JAZZ This is a Bullish Sentiment, not Bearish you dummy

0 · Reply

Fosco_ Oct. 2 at 10:09 AM

$AVDL Pre market is unusually low. I guess this is pure manipulation on low volume as fact is that AVDL is on the shore of getting a stellar win on $JAZZ

1 · Reply

SweepCastApp Oct. 2 at 1:11 AM

$JAZZ: Unusual Options Activity Alerted CALL flow observed 256x contracts at Strike price of $160 Exp on 01/16/2026 with Premium of $128K and showing BEARISH Sentiment

0 · Reply

JFDI Oct. 1 at 7:29 PM

$JAZZ B/O

0 · Reply

DragonTiger Oct. 1 at 12:51 AM

$JAZZ get back to 140 ~ in in October. $GS has a PT of 190

0 · Reply

ChartMill Sep. 30 at 1:28 PM

Cannabis Stocks: 3 Setups to Watch Closely 🌱📈 The cannabis sector lit up on Monday after President Trump highlighted CBD as a potential “revolution” for elderly healthcare. Stocks like TLRY, GRWG, and CGC exploded higher, but instead of chasing the names that already ran, smart traders are scanning for setups that haven’t broken out yet. $MO - $ABBV - $JAZZ https://chartmill.substack.com/p/cannabis-stocks-surge-but-these-setups

0 · Reply

Quantumup Sep. 30 at 12:21 PM

Stifel reiterated $ALKS Buy-$42 $CNTA $AXSM $JAZZ $AVDL Stifel said: We remain optimistic on the prospects of ALKS2680/alixorexton in NT2, where we think (1) the drug is likely to work, (2) the efficacy bar is actually quite low-drugs historically are only generating ~2-11 minute absolute benefits on MWT and (3) Wall Street safety/ tolerability concerns are overdone. On points #1/2, we think there is a lot of room/ margin in NT2 for ALKS2680 to put up a clinical effect that is materially less than observed in the small ph1b, but still superior to standard-of-care. And on point #3, based on our KOL checks, it has actually been difficult to find a physician who is concerned around visual AEs. The bear case on NT2 is that visual AEs could be worse, but, because these patients have "normal" orexin, efficacy may be more modest -- in our opinion, though, you can't have it both ways.

0 · Reply

jo4vie_brock Sep. 29 at 7:07 PM

$JAZZ

0 · Reply

SweepCastApp Sep. 29 at 3:45 PM

$JAZZ: Unusual Options Activity Alerted CALL flow observed 15x contracts at Strike price of $130 Exp on 05/15/2026 with Premium of $28K and showing NEUTRAL Sentiment

0 · Reply

stockmando Sep. 29 at 4:32 AM

Leaders in medical cannabis: $ACB $TLRY $CGC $MSOS $JAZZ

0 · Reply

KevinC11 Sep. 29 at 3:17 AM

$IXHL <—- $RMD $JAZZ $JNJ

0 · Reply

StonkCapital Sep. 28 at 11:39 PM

$CWBHF $JAZZ $YCBD $MSOS $TLRY The Trump video mentions Medicare coverage for CBD!!! This is huge. https://x.com/TheDankInformer/status/1972430155797921811?t=xoIJBsaGmvlYa9zdI7SdTQ&s=19

1 · Reply

va4f6 Sep. 28 at 11:26 PM

$IXHL $RMD has their TOP (OSA) doctor Alison Williamson on the $IXHL REOSA Advisory Board along with 2 other Big Pharma doctors from $JAZZ Dr Lou Barbato and $NVO Dr Williams are ALL on the $IXHL REPOSA Advisory Board presently because REPOSA is a REVOLUTIONARY therapy treating (OSA) Sleep Apnea with just a PILL and the Phase 2 results were outstanding with NO SIDE EFFECTS!! Marketwatch 1 year PT $34.27

0 · Reply

Market Cap	8.46B
Revenue (ttm)	4.07B
Net Income (ttm)	560.12M
EPS (ttm)	N/A
PE Ratio	44.40
Forward PE	80.57
Profit Margin	13.77%
Debt to Equity Ratio	1.45

Volume	1,087,600
Avg Vol	793,236
Day's Range	N/A - N/A
Shares Out	60.66M
Stochastic %K	81%
Beta	0.28
Analysts	Strong Sell
Price Target	$186.94